PDLI EBITDA Growth
Pdl Biopharma Inc · EBITDA Growth
PDLI EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-402.06%period ending
PDLI TTM EBITDA YoY % (-114.29% → -402.06%)
Year-over-year change
High-resolution chart · PNG
PDLI ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -402.0551% | |
| -239.1427% | |
| -330.3546% | |
| -97.3974% | |
| 265.8125% | |
| 458.152% | |
| -112.1793% | |
| -112.1725% | |
| -112.3318% | |
| -113.8424% | |
| 205.891% | |
| 64.3539% | |
| -41.1916% | |
| -51.4886% | |
| -86.036% | |
| -74.9428% | |
| -36.2328% | |
| -29.113% | |
| -6.6522% | |
| 3.0657% | |
| -11.3796% | |
| 11.1686% | |
| 13.0408% | |
| 25.0421% | |
| 35.9945% | |
| 22.6744% | |
| 28.5475% | |
| 21.077% | |
| 18.4002% | |
| 15.7984% | |
| 11.0164% | |
| 3.5311% | |
| 37.3372% | |
| 40.7662% | |
| 53.8329% | |
| 77.5919% | |
| -9.0877% | |
| -9.5125% | |
| -25.3995% | |
| -35.3933% | |
| -6.525% | |
| -8.9034% | |
| 35.5036% | |
| 173.0173% | |
| 332.7424% | |
| 1,785.5722% | |
| 2,956.7286% | |
| 79.9559% | |
| 907.131% | |
| 315.5718% | |
| 125.6055% | |
| 260.3175% | |
| -253.4807% | |
| 77.0131% | |
| 11.057% | |
| 63.0535% | |
| 106.0497% | |
| 60.3387% | |
| 69.689% | |
| -201.5529% | |
| 0.0795% | |
| 15.2003% | |
| 18.4186% | |
| 69.6181% | |
| -77.3883% | |
| -118.2041% | |
| -61,334.9515% | |
| -322,265.7143% | |
| -1,984.7858% | |
| -579.6777% | |
| -98.3638% | |
| -99.7958% | |
| -87.8516% | |
| -51.7781% | |
| -29.3173% | |
| 62.4183% | |
| 1,041.957% | |
| 275.9586% | |
| 698.5215% | |
| 255.1912% | |
| 133.6552% | |
| 193% | |
| 49.5593% | |
| 16.0494% | |
| 69.9482% | |
| 74.7619% | |
| 71.3592% | |
| 60.8696% | |
| -201.5625% | |
| -114.2857% |